Background: Previous observational studies reported an increased prevalence of asthma in migraine patients. Whether triptans affect the asthma risk has not yet been explored in an epidemiological study.
Objective: To estimate the risk of newly diagnosed asthma in patients with a general practitioner-diagnosed migraine in the UK between 1994 and 2001.
Methods: A population-based follow-up study and a nested case-control analysis were conducted using the General Practice Research Database.
Results: The study encompassed 51,688 migraineurs and the same number of matched controls. In the follow-up analysis, the relative risk of developing asthma in migraineurs compared with non-migraineurs was 1.3 (95% confidence interval [CI] 1.1-1.4). In the nested case-control analysis, the adjusted odds ratio for asthma in migraineurs overall was 1.17 (95% CI 1.01-1.35), and for those with a recent triptan prescription 1.12 (95% CI 0.65-1.94).
Conclusion: The risk of developing asthma was not materially altered for patients with a general practitioner-recorded migraine diagnosis, regardless of triptan use.